Research findings answer many clinical questions on how to tailor interventions to varying adolescent patient characteristics based on individual and family factors.
Teenagers who suffer from antidepressant-resistant depression and have a concurrent history of family conflict, nonsuicidal self injury, or more severe symptoms of depression will likely have a poorer response to a new course of treatment, according to a study published in the March Journal of the American Academy of Child and Adolescent Psychiatry.
The study also found that adding cognitive-behavioral therapy (CBT) to antidepressant medications produces the most benefit for patients who have comorbidities such as anxiety disorders.
The study's findings can help clinicians individualize treatment plans for adolescents with more chronic and complicated forms of depression.
Analyzing the data from the Treatment-Resistant Depression in Adolescents (TORDIA) study, Joan Asarnow, Ph.D., a professor of psychiatry and behavioral sciences at the University of California at Los Angeles (UCLA) and the principal investigator of TORDIA at UCLA, and coauthors identified a number of patient characteristics that are associated with the likelihood of response to treatment and the benefit of medication—CBT combination therapy versus medication alone in this hard-to-treat population.
READ MORE @ PSYCHIATRIC NEWS
Showing posts with label cognitive behavioural therapy (CBT). Show all posts
Showing posts with label cognitive behavioural therapy (CBT). Show all posts
Tuesday, April 7, 2009
Thursday, October 30, 2008
Drug-therapy combo best for anxiety in kids -study
A combination of a common antidepressant and a specialized form of talk therapy offer the best treatment for children and youth with anxiety disorders, U.S. researchers said on Thursday.
The findings come from the largest study of anxiety in children yet and offer much-needed guidance about how best to treat young people with separation anxiety, social phobia and generalized anxiety disorder -- conditions that affect as many as 20 percent of children and teenagers in the United States.
The study "clearly showed that combination treatment is the most effective for these children," Dr. John Walkup of Johns Hopkins University in Baltimore, who worked on the study, said in a statement.
But he said either therapy alone or sertraline alone helped well. Sertraline is the generic name of Pfizer Inc's (PFE.N: Quote, Profile, Research, Stock Buzz) Zoloft, which is one of a class of antidepressants called selective serotonin reuptake inhibitors.
READ MORE @ REUTERS
The findings come from the largest study of anxiety in children yet and offer much-needed guidance about how best to treat young people with separation anxiety, social phobia and generalized anxiety disorder -- conditions that affect as many as 20 percent of children and teenagers in the United States.
The study "clearly showed that combination treatment is the most effective for these children," Dr. John Walkup of Johns Hopkins University in Baltimore, who worked on the study, said in a statement.
But he said either therapy alone or sertraline alone helped well. Sertraline is the generic name of Pfizer Inc's (PFE.N: Quote, Profile, Research, Stock Buzz) Zoloft, which is one of a class of antidepressants called selective serotonin reuptake inhibitors.
READ MORE @ REUTERS
Tuesday, September 16, 2008
Study rejects cost-effectiveness of CBT for adolescents
Cognitive behavioural therapy (CBT) for clinically depressed adolescents is not cost effective, researchers have found.
For those with moderate to severe major depression, the addition of CBT to drug therapy and active clinical care does not improve wellbeing enough to justify the cost, researchers have found.
The research team at the National Institute for Health Research Health Technology Assessment (NIHR HTA) compared the clinical benefits and cost-effectiveness of two treatments for depression.
READ MORE @ MANAGEMENT PRACTICE
For those with moderate to severe major depression, the addition of CBT to drug therapy and active clinical care does not improve wellbeing enough to justify the cost, researchers have found.
The research team at the National Institute for Health Research Health Technology Assessment (NIHR HTA) compared the clinical benefits and cost-effectiveness of two treatments for depression.
READ MORE @ MANAGEMENT PRACTICE
Wednesday, June 4, 2008
£1.2M trial to test effectiveness of cognitive behavioral therapy
Study to map effectiveness of CBT for patients who have not responded to antidepressants
A team of researchers, led by Dr Nicola Wiles at the University of Bristol and involving researchers from the Peninsula Medical School in the South West, has been awarded £1.2 million by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme for a clinical trial to investigate the effectiveness of cognitive behavioural therapy (CBT) for patients with depression who do not respond to treatment with antidepressants.
Patients who have been taking antidepressants for at least six weeks will be invited to participate in the trial and receive either CBT in addition to their medication, or continue with usual care from their general practitioner (including medication). Both groups will be followed up for 12 months to see which approach is the most effective in reducing depressive symptoms and improving quality of life. Recruitment for the trial is due to start in the autumn.
The Bristol team, in partnership with researchers from the University of Exeter, the Peninsula Medical School, the University of Glasgow and the Avon and Wiltshire Mental Health Partnership, will also evaluate the cost-effectiveness of the treatment and patients' views and experiences of it.
Dr Nicola Wiles said: "CBT has been shown to help patients with depression but there is currently little evidence about what alternative treatment options doctors should discuss with patients who do not get better with antidepressants. Improving access to psychological therapies is a Government priority, so it is important that we conduct studies such as this to help inform the care of people with depression."
READ MORE @ EUREKALERT
A team of researchers, led by Dr Nicola Wiles at the University of Bristol and involving researchers from the Peninsula Medical School in the South West, has been awarded £1.2 million by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme for a clinical trial to investigate the effectiveness of cognitive behavioural therapy (CBT) for patients with depression who do not respond to treatment with antidepressants.
Patients who have been taking antidepressants for at least six weeks will be invited to participate in the trial and receive either CBT in addition to their medication, or continue with usual care from their general practitioner (including medication). Both groups will be followed up for 12 months to see which approach is the most effective in reducing depressive symptoms and improving quality of life. Recruitment for the trial is due to start in the autumn.
The Bristol team, in partnership with researchers from the University of Exeter, the Peninsula Medical School, the University of Glasgow and the Avon and Wiltshire Mental Health Partnership, will also evaluate the cost-effectiveness of the treatment and patients' views and experiences of it.
Dr Nicola Wiles said: "CBT has been shown to help patients with depression but there is currently little evidence about what alternative treatment options doctors should discuss with patients who do not get better with antidepressants. Improving access to psychological therapies is a Government priority, so it is important that we conduct studies such as this to help inform the care of people with depression."
READ MORE @ EUREKALERT
Subscribe to:
Posts (Atom)
